A Phase 2 interventional study of Zimura and Eylea in Idiopathic Polypoidal Choroidal Vasculopathy, sponsored by Ophthotech Corporation. Withdrawn at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-02-21.
Sponsored by Ophthotech Corporation (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
To asses the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Eylea® in treatment experienced subjects with idiopathic polypoidal choroidal vasculopathy
54 studies on the registry are indexed under Polypoidal Choroidal Vasculopathy; 6 are open to participants now.
Browse Polypoidal Choroidal Vasculopathy studies →Ophthotech Corporation is the lead sponsor of 13 studies on the registry; none are open to participants now.
First submitted before Ophthotech Corporation became part of Astellas Pharma Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zimura dosage 1 + Eylea 2 mg
Drug: Zimura · Drug: Eylea
Zimura dosage 2 + Eylea 2 mg
Drug: Zimura · Drug: Eylea
Adverse Events (AEs)
AEs
Time frame: 9 months
Start is estimated for Nov 2018; primary completion for Dec 2019, 13 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Avacincaptad pegol · Aflibercept
Polypoidal Choroidal Vasculopathy →